Antisense Therapeutics To Present At Sachs Associates 7th Annual North America Forum For Investing And Partnering In Biotech
Mark Diamond, Antisense Therapeutics Chief Executive Officer, will give a presentation on February 25 at 11:30 a.m. ET on the Company and its lead compound, ATL1102, which is currently in Phase IIa clinical trials as a treatment for multiple sclerosis (MS). The presentation will be followed by a question and answer session and a live webcast may be accessed here.
A replay of the presentation will be archived for 12 months after the conference, at the same website link. For more information about Sachs Associates 7th Annual North America Forum for Investing and Partnering in Biotech, please visit the Sachs Associates website at http://www.sachsforum.com.
Antisense management will be available for meetings in Boston on February 25-26, and in New York on February 27-28.
The Company's current Phase IIa trial is a study in 77 patients to assess the safety and efficacy of ATL1102 as a treatment for relapsing remitting MS. Results are anticipated by mid-year 2008.
ATL1102 is a second-generation antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4). It is believed that the inhibition of VLA-4 prevents white blood cells from entering sites of inflammation, thereby halting the progression of inflammatory diseases such as MS. VLA-4 is a clinically validated target in the treatment of MS. Antisense inhibition of VLA-4 has demonstrated positive effects in an animal model of MS and the data has been published -- Myers et al., J Neuroimmunol 160, 12-24 (2005).
About Antisense Therapeutics Limited
Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialize novel antisense pharmaceuticals for large unmet markets. Antisense Therapeutics' strategic technology partner is Isis Pharmaceuticals Inc. ANP has two drugs in development and two drugs in pre-clinical research. Its lead drug, ATL1102, is in the advanced stages of a Phase IIa trial as a potential treatment of multiple sclerosis.
Antisense Therapeutics Limited
Antisense therapeutics sã prezinte, la Sachs, asociaþi 7a anual America de Nord forum pentru a investi în biotehnologie ºi Parteneriat - Antisense Therapeutics To Present At Sachs Associates 7th Annual North America Forum For Investing And Partnering In Biotech - articole medicale engleza - startsanatate